Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petose
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).
Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh